Infectious disease practices carry an average claim denial rate of 9%, above the cross-specialty average of 5-7%. The complexity of the specialty drives this gap: infusion billing rules, consult-versus-E/M coding distinctions, and medical necessity documentation for antimicrobial therapy each create multiple failure points. Left unworked, denials in infectious disease practices compound quickly because IV drug claims carry higher average reimbursement than standard office visit claims. MMBS resolves infectious disease denials at an 85% first-pass resolution rate by applying payer-specific appeal templates and specialty-trained coders who understand the nuances of infusion and lab billing.
CO-16: Missing or Insufficient Information
CARC code CO-16 (claim or service lacks information or has submission or billing errors) is the most frequent denial in infectious disease billing. CO-16 covers a wide range of issues: missing drug quantity on J-code lines, absent infusion start/stop times, incomplete diagnosis codes, and missing ordering provider NPI on laboratory tests. The root cause in infectious disease is typically clinical staff documentation gaps on infusion logs. When a nurse administers ceftriaxone 2g IV but records only the drug name without start and stop times, the resulting claim lacks the supporting data payers require to adjudicate the infusion codes (96365-96366). Prevention requires standardized infusion intake forms with mandatory time fields and a pre-submission coding review for completeness.
CO-4: Inconsistent Modifier Usage
CARC code CO-4 (service inconsistent with modifier) affects infectious disease claims when modifiers are missing, incorrect, or applied to incompatible codes. The two most common CO-4 scenarios: billing an E/M code on the same date as an infusion without modifier 25, and applying modifier 59 (distinct procedural service) incorrectly to separate concurrent infusion lines instead of modifier 91 (repeat clinical diagnostic lab test). Modifier 25 is required on the E/M when the physician performs a separately identifiable visit in addition to the infusion. Without modifier 25, the payer bundles the E/M into the infusion reimbursement and issues CO-4 or CO-97. MMBS coders apply a pre-submission modifier check to all same-day E/M and infusion claims.
CO-97: Unbundling and Bundling Edits
CARC code CO-97 (payment included in allowance for another service) appears on infectious disease claims when infusion codes are billed incorrectly relative to the CCI (Correct Coding Initiative) edits published by CMS. CCI edits define which code pairs are considered integral to each other and cannot be billed separately. The most common CO-97 trigger: billing CPT 96365 twice for the same drug instead of 96365 for hour one and 96366 for each additional hour. Another common trigger: billing 96367 (concurrent infusion) when the second drug actually runs after the first completes, which should be coded as a sequential additional infusion instead. Reviewing CCI edit tables quarterly and training nursing staff on infusion documentation prevents most CO-97 denials.
CO-22: Coordination of Benefits
CARC code CO-22 (patient has other insurance that is primary) is a coordination of benefits denial indicating that a secondary payer received a claim without a primary payer’s explanation of benefits (EOB) on file. Infectious disease patients with complex conditions such as HIV (B20) or cancer-associated infections frequently carry dual coverage: Medicare as primary and Medicaid or supplemental insurance as secondary. When registration staff do not capture the correct primary payer or do not update insurance changes, the claim routes to the wrong payer first and generates a CO-22. Prevention requires a real-time eligibility check at each visit and a documented process for patients who report insurance changes at the desk.
Prior Authorization Denials
Beyond standard CARC codes, infectious disease practices frequently receive prior authorization denials for long-course IV antibiotics and antifungals. Payers such as UnitedHealthcare and Cigna require authorization for outpatient IV antibiotic courses exceeding 10-14 days, and the authorization must specify the drug, dose, and estimated duration. When authorization is absent or the treatment duration extends beyond the approved window without a renewal, claims deny under CO-4 or a payer-specific authorization reason code. MMBS maintains a prior authorization tracking calendar for each infectious disease client, flagging renewal windows 5 days before expiration.